Error: INTERNAL_ERROR for 61c6e044-36ec-bd96-e40a-75ccf9efdd5c: {"response":{"errors":[{"message":"INTERNAL_ERROR for 61c6e044-36ec-bd96-e40a-75ccf9efdd5c","locations":[{"line":74,"column":7}],"path":["youmightlike"],"extensions":{"classification":"INTERNAL_ERROR"}}],"data":{"articleData":{"uri":"/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials/","canonicalUrl":"https://www.lawjournalnewsletters.com/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials/","generatedId":"glf45ggeif","naturalId":"blogAndPostId/blog/post/382-33152","type":"ARTICLE","postFormat":"news","kickerPresentedBy":null,"presentedBy":"","title":"From the PTO to the FDA: What to Consider When Branding Clinical Trials","readtime":"11","timeToRead":"11 minute","prettyModified":null,"prettyDateTime":"February 01, 2021 at 03:22 AM","needToKnow":[],"byline":"Brandon Leahy Susanna Lichter and Eva Yin","authors":[{"name":"Brandon Leahy Susanna Lichter","description":"","imageLarge":"https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g","webUrl":"/author/profile/brandon-leahy-susanna-lichter/"},{"name":"Eva Yin","description":"","imageLarge":"https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g","webUrl":"/author/profile/eva-yin/"}],"publication":"Law Journal Newsletters","kicker":"Features","kickerNode":[{"name":"Features","slug":"features-kicker","uri":"/features/","sectionName":"Features"}],"prettyDate":"February 01, 2021","pubDate":"2021-02-01 03:22:06.000","modifiedDate":"","isDownload":"false","primaryCategory":{"channelName":"","sectionName":"","name":"","uri":"","slug":"","channelUri":""},"tags":[],"image":{"uri":"https://images.lawjournalnewsletters.com/contrib/content/uploads/sites/382/2017/12/fda2.jpg","width":"0","height":"0"},"embed1":"","embed2":"","summary":"The legal implications of branding generally arise initially for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.","categories":[{"name":"Features","uri":"/features/","channelName":"Kicker"},{"name":"The Intellectual Property Strategist","uri":"/ljn-newsletters/intellectual-property-strategist/","channelName":"LJN Newsletters"},{"name":"Intellectual Property","uri":"/intellectual-property/","channelName":"Topics"},{"name":"Litigation","uri":"/litigation/","channelName":"Topics"},{"name":"Patent Licensing and Transactions","uri":"/patent-licensing-and-transactions/","channelName":"Topics"},{"name":"Regulation","uri":"/regulation/","channelName":"Topics"}],"bodyArray":["

The legal implications of branding generally arise for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.

","

Our experience and observations suggest that branding clinical trials has become more prevalent. While it may seem unnecessary to brand a clinical trial because of its limited duration and pre-market nature, the long road to market for therapeutics makes building a recognizable house brand or product name challenging for companies before regulatory approval. As a result, companies are turning to the clinical trial process as an early-phase opportunity to establish a brand identity, raise public awareness of the company's mission, and create market familiarity with the company's technology and discovery objectives.

"],"altLangHeadline":"","altLangBodyArray":[],"slides":[]},"youmightlike":null,"readnext":{"contents":[{"uri":"/2016/08/01/the-article-8-opt-in-2/","title":"The Article 8 Opt In","prettyDate":"","summary":"The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.","description":"The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.","kicker":"","image":{"uri":"https://feature.law.com/environments/stage/static/default-article-image.png","width":"0","height":"0"},"primaryCategory":{"name":"","uri":"","channelName":"","channelUri":""},"publication":"Law Journal Newsletters"},{"uri":"/2013/02/28/major-differences-in-uk-u-s-copyright-laws/","title":"Major Differences In UK, U.S. Copyright Laws","prettyDate":"","summary":"This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.","description":"This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.","kicker":"","image":{"uri":"https://feature.law.com/environments/stage/static/default-article-image.png","width":"","height":""},"primaryCategory":{"name":"","uri":"","channelName":"","channelUri":""},"publication":"Law Journal Newsletters"},{"uri":"/2019/10/01/legal-possession-what-does-it-mean/","title":"Legal Possession: What Does It Mean?","prettyDate":"","summary":"Possession of real property is a matter of physical fact. Having the right or legal entitlement to possession is not \"possession,\" possession is \"the fact of having or holding property in one's power.\" That power means having physical dominion and control over the property.","description":"Possession of real property is a matter of physical fact. Having the right or legal entitlement to possession is not \"possession,\" possession is \"the fact of having or holding property in one's power.\" That power means having physical dominion and control over the property.","kicker":"Features","image":{"uri":"https://images.lawjournalnewsletters.com/contrib/content/uploads/sites/382/2019/09/house_key.jpg","width":"616","height":"372"},"primaryCategory":{"name":"","uri":"","channelName":"","channelUri":""},"publication":"Law Journal Newsletters"},{"uri":"/2024/08/01/warehouse-liability-know-before-you-stow/","title":"Warehouse Liability: Know Before You Stow!","prettyDate":"August 01, 2024","summary":"As consumers continue to shift purchasing and consumption habits in the aftermath of the pandemic, manufacturers are increasingly reliant on third-party logistics and warehousing to ensure their products timely reach the market.","description":"As consumers continue to shift purchasing and consumption habits in the aftermath of the pandemic, manufacturers are increasingly reliant on third-party logistics and warehousing to ensure their products timely reach the market.","kicker":"Features","image":{"uri":"https://images.lawjournalnewsletters.com/contrib/content/uploads/sites/382/2024/07/warehouse2.jpg","width":"620","height":"372"},"primaryCategory":{"name":"","uri":"","channelName":"","channelUri":""},"publication":"Law Journal Newsletters"},{"uri":"/2021/08/01/strategy-vs-tactics-two-sides-of-a-difficult-coin/","title":"Strategy vs. Tactics: Two Sides of a Difficult Coin","prettyDate":"August 01, 2021","summary":"With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.","description":"With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.","kicker":"Features","image":{"uri":"https://images.lawjournalnewsletters.com/contrib/content/uploads/sites/382/2021/07/strategy4.jpg","width":"616","height":"372"},"primaryCategory":{"name":"","uri":"","channelName":"","channelUri":""},"publication":"Law Journal Newsletters"}]}},"extensions":{"DateTime":"2025-06-14T11:36:25.159879827","ResponseTime":"?","AuthorizedUser":false,"AlmContext":"AlmContext{clientIP='10.0.253.240', internalIP='true', origin='', authorizedUser='false', Chinchilla, userAccount='null', UCID=null, ipAccount='null'}","NavServiceResponse":{"message":"Show a wall","action":"show wall","data":"PayWallExcludedClient","placResultsPublic":{"overallContentType":"ExcludedContent","userState":"DENYNOSUB","showWall":"PayWallExcludedClient","userAccess":"0","referrer":"","userAccessCookie":null,"productList":"","contentMetaData":"

ARTICLE/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials/Law Journal Newsletters2021-02-01 03:22:06

Law Journal Newsletters

Features

The Intellectual Property Strategist

Intellectual Property

Litigation

Patent Licensing and Transactions

Regulation

","numberOfViewsLeft":0,"numberOfFCFViewsLeft":0,"decisionEngine":"RidgeRunner","rulesFiredString":"[]","contentProductCodes":"[\"ljnip\",\"//ljnip\"]"}},"DebuggingData":null,"UsedCache":"true","DataUrl":"http://ml.alm.com:9016/bff-services/content/get-you-may-like-for-content.xqy?naturalId=/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials&site=www.lawjournalnewsletters.com&total="},"status":200,"headers":{}},"request":{"query":"query LawJournalNewsletterscom__Article{articleData:\n getContent(naturalId: \"/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials\", site:\"lawjournalnewsletters.com\") {\n uri\n canonicalUrl\n generatedId\n naturalId\n type\n postFormat\n kickerPresentedBy {\n \t\t label\n \t\t value\n \t\t}\n presentedBy\n title\n readtime\n timeToRead\n prettyModified\n prettyDateTime\n needToKnow\n byline\n authors {\n name\n description\n imageLarge\n webUrl\n }\n publication\n kicker\n kickerNode {\n name\n slug\n uri\n sectionName\n }\n prettyDate\n prettyDateTime\n pubDate\n modifiedDate\n isDownload\n primaryCategory {\n channelName\n sectionName\n name\n uri\n slug\n channelUri\n }\n tags\n image {\n uri\n width\n height\n }\n embed1\n embed2\n summary\n categories {\n name\n uri\n channelName\n }\n bodyArray\n altLangHeadline\n altLangBodyArray\n slides {\n image\n caption\n height\n width\n }\n\n\n }\n youmightlike:\n getYouMayLikeForContent(naturalId: \"/2021/02/01/from-the-pto-to-the-fda-what-to-consider-when-branding-clinical-trials\", site:\"lawjournalnewsletters.com\") {\n uri\n title\n byline\n authors {\n name\n description\n imageLarge\n webUrl\n jobTitle\n }\n prettyDate\n readtime\n image {\n uri\n width\n height\n }\n summary\n }\n readnext:\n getStatsList(site:\"lawjournalnewsletters.com\", topic: \"\", limit: 5, timeframe: \"30days\" ) {\n contents {\n uri\n title\n prettyDate\n summary\n description\n kicker\n image {\n uri\n width\n height\n }\n primaryCategory {\n name\n uri\n channelName\n channelUri\n }\n publication\n }\n\n }\n }"}}

Law.com Subscribers SAVE 30%